- Home
- MNY vs BTAI Comparison
MNY vs BTAI Comparison
Compare MNY & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNY | BTAI |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MNY | BTAI |
|---|---|---|
| Price | $1.25 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $26.67 |
| AVG Volume (30 Days) | 56.4K | ★ 568.3K |
| Earning Date | 12-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,182,746.00 | $752,000.00 |
| Revenue This Year | $11.26 | N/A |
| Revenue Next Year | $20.70 | $441.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $1.17 |
| 52 Week High | $2.40 | $8.08 |
Technical Indicators
Market Signals| Indicator | MNY | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 54.43 |
| Support Level | $1.26 | $1.50 |
| Resistance Level | $1.32 | $2.12 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 0.71 | 72.58 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.